Literature DB >> 3819804

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

G N Hortobagyi, G P Bodey, A U Buzdar, D Frye, S S Legha, R Malik, T L Smith, G R Blumenschein, H Y Yap, V Rodriguez.   

Abstract

Fifty-nine evaluable patients under 65 years of age with measurable metastatic breast cancer and without prior chemotherapy were randomly assigned to treatment with fluorouracil, Adriamycin (Adria Laboratories, Columbus, OH), and cyclophosphamide (FAC) at standard or high doses (100% to 260% higher than standard FAC) following a dose escalation schedule. Patients randomized to the high-dose FAC received the first three cycles of therapy within a protected environment. Subsequent cycles for this group were administered at standard doses of FAC in an ambulatory setting, the same as for the control group. After reaching 450 mg/m2 of Adriamycin, patients in both groups continued treatment with cyclophosphamide, methotrexate, and fluorouracil until there was disease progression. Analysis of pretreatment patient characteristics showed an even distribution for most known pretreatment factors, although the control group had slightly (but nonsignificantly) more favorable prognostic characteristics. Fourteen patients (24%) achieved a complete remission (CR) and 32 (54%) achieved a partial remission (PR), for an overall major response rate of 78%. There were no differences in overall, CR, or PR rates between the high-dose FAC and control groups. The median response durations were 11 and 10 months for the protected environment and control groups, respectively, and the median survival was 20 months for both groups. Hematologic, gastrointestinal (GI), and infection-related complications were significantly more frequent and severe in the group treated with high-dose chemotherapy. Stomatitis, diarrhea, and skin toxicity were dose-limiting. However, there were no treatment-related deaths. High-dose induction combination chemotherapy with the agents used in this study failed to increase the response rate or survival duration, and resulted in a substantial increase in toxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3819804     DOI: 10.1200/JCO.1987.5.3.354

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

Review 1.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 3.  Dose-intensified treatment of breast cancer: current results.

Authors:  C von Schilling; F Herrmann
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

4.  Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Authors:  C Walsh; R H Blum; R Oratz; A Goldenberg; A Downey; J L Speyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer.

Authors:  F Porzsolt; G Meuret; E D Kreuser; S Mende; L Buchelt; P Strigl; M Redenbacher; F Klumpp; M Schmelz; R Knöchelmann
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

6.  Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF).

Authors:  J A Neidhart
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

Review 7.  Breast cancer (metastatic).

Authors:  Justin Stebbing; Sarah Ngan
Journal:  BMJ Clin Evid       Date:  2010-09-08

Review 8.  Breast cancer (metastatic).

Authors:  Justin Stebbing; Sarah Slater; Maurice Slevin
Journal:  BMJ Clin Evid       Date:  2007-02-01

9.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

Authors:  Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri
Journal:  J Control Release       Date:  2016-03-24       Impact factor: 9.776

Review 10.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.